Steven Baldwin is a partner in Kirkland’s IP Litigation team in London with significant experience representing clients in patent, life sciences regulatory, copyright, trademark and trade secrets matters. His practice focuses primarily on complex cross-border telecommunications (SEP/FRAND) and life sciences patent disputes and former employee trade secrets cases. Steven has developed a particular interest in, and deep knowledge of, the law governing supplementary protection certificates and is recognised as a thought leader and regular writer, speaker and commentator on the topic.
Steven’s case experience covers a broad range of technical fields including 3GPP, 3GPP2, DMR, TETRA and other wireless (standardised and non-standardised) mobile telecommunications technologies, organic chemistry, antibody biologics, biological product development and screening platforms, formulation science, next generation cancer treatments, and e-cigarette/vaping technologies.
Steven also has significant non-contentious IP experience including billion-dollar IP portfolio purchases, global strategic IP portfolio strategies, and business-critical licensing deals, as well as advising on image rights, sponsorship and global celebrity advertising campaigns for world-renowned soccer clubs and automotive clients.
Steven was recognized as a Rising Star in IP by Managing Intellectual Property in 2018 and 2019 and as a Recommended Individual in JUVE Patent 2020.
“Asking AI to explain itself – a problem of sufficiency,” Managing Intellectual Property, 2020
“From Takeda to Teva v Merck: Are we treading the right path on combination product SPCs?” (Part 2 of 2) European Intellectual Property Review, 2017
“The definition of product in the SPC Regulation: (Part 1 of 2) What's in a name?” European Intellectual Property Review, 2017
“Teva v Gilead, Abraxis v Comptroller and Wobben v Siemens kick of 2017's patent cases”, The IPKat, 2017
Speaker, “SEP case law developments in the EU (UK, France and Netherlands)”, Fair Standards Alliance General Assembly, 2020
Speaker, “Should FRAND Licensing Rates be Global?” and “An International Trade and Enforcement Perspective on FRAND”, OxFirst Intellectual Property and Competition Forum, Brussels, 2020
Speaker, “SPCs - Recent Developments”, EPLAW Congress, Brussels, 2019
Speaker, “Introduction to SPCs and Second Medical Use”, ERA Conference, Brussels, 2018
Speaker, Roundtable on Pharmaceutical Incentives, ERA Conference, Brussels, 2018
Speaker, “Identifying the Effects of Brexit on the Protection and Enforcement of IP Rights”, The Knowledge Group, Webcast, 2017
Speaker, “Update and forecast on SPCs”, EPLAW Congress, Brussels, 2016
“Court of Appeal rules Xiaomi may continue to sell products in the Netherlands,” JUVE Patent, March 2020
Quoted “COVID-19: Patents are not adequate incentives for vaccine research,” Managing Intellectual Property, March 2020
Quoted “What Brexit Will Mean For Intellectual Property Law,” Law360, January 2020
Quoted “Untangling the wires of global FRAND,” JUVE Patent, October 2019
Quoted “FRAND At UK's Top Court: What You Need To Know,” Law360, October 2019
Quoted “In-House Counsel Should Pay Attention to Court Rulings in FRAND Litigation,” Corporate Counsel, August 2019
Quoted “Stockpile fears - The SPC manufacturing waiver has now come into effect, with both the generic and innovator industries unhappy with aspects of the new legislation,” Intellectual Property Magazine, August 2019
Quoted “Analysis: CJEU SPC Basic Patent Ruling 'Doesn't give any more clarity',” Managing Intellectual Property, August 2018
Memberships & Affiliations
The Law Society of England & Wales
AIPPI: International Association for the Protection of Intellectual Property
Admissions & Qualifications
- 2012, Admitted to practice as a Solicitor of England and Wales
- Oxford UniversityPostgraduate Diploma in Intellectual Property Law and Practice2013
- College of LawLegal Practice Course2009
- University of OxfordB.A., Jurisprudence2008First class mark in Patent and Copyright Law